Goldman Sachs has won its fourth drugs mandate in a month after advising a US company on its sale to Merck, the German pharmaceuticals company.

Goldman is advising Sirna Therapeutics, a US biotechnology company on its $1.1bn (€865m) sale to Merck according to a Sirna spokesman. JP Morgan is Sirna's usual adviser according to Standard & Poor's data provider Capital IQ.